Ali Butt
Exploring the select efficacy of sailuotong (SLT) constituents and metabolites in people with mild cognitive impairment
Dementia is a syndrome associated with cognitive decline, leading to decreased function and poor quality of life. The onset of dementia can result from a range of modifiable (exercise, education, diet etc.) and non-modifiable (genetic mutations and predispositions) factors. The number of people living with dementia worldwide is projected to increase to 139 million by 2050 and expected to cost the Australian healthcare system more than $15 billion dollars (AUD) annually. Currently, there is a significant lack in effective pharmacological therapies to treat cognitive impairment forms such as Mild cognitive impairment (MCI) and Alzheimer's disease (AD)
Sailuotong (SLT) is a standardised medicinal herbal formula specifically designed to address the complex mechanisms behind dementia. This MRes project aims to establish and optimise a method to quantify SLT marker compounds and metabolites in human plasma and to assess any association of these concentrations with clinical outcomes. These data may inform further research using SLT, as well as its characterisation in blood plasma.
Supervisors:
